ArticleEuropean journal of medical research2025
Association between the systemic immune-inflammation index and mortality risk in myocardial infarction patients: a retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The systemic immune-inflammation index in coronary heart disease: a narrative review of thromboinflammation, phenotype-dependent utility, and clinical translation.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundThe systemic immune-inflammation index (SII) has shown potential as a prognostic biomarker in several diseases. This study aimed to investigate the relationship between SII and mortality in patients with myocardial infarction (MI).
methodsA retrospective cohort study was conducted from the MIMIC-Ⅳ database (n = 774) and Harbin Medical University Cancer Hospital (n = 482). Patients were divided into four quartiles based on SII, and mortality at 28, 90, and 180 days was analyzed. Kaplan-Meier survival curves and Cox regression models adjusted for confounders were used to assess the relationship between SII and mortality. Additionally, restricted cubic splines (RCS) were used to explore the nonlinear relationship between SII and 28-day mortality.
resultsRCS analysis revealed a significant nonlinear J-shaped association between SII and mortality risk, with the lowest mortality risk observed at approximately 770 × 10⁹/L of SII. In quartile analysis, the highest SII (Q4) had significantly higher mortality rates at 28 days (30.93% vs. 8.29%, P < 0.001), 90 days (38.14% vs. 11.92%, P < 0.001), and 180 days (42.78% vs. 12.44%, P < 0.001), while the lowest SII group (Q1) demonstrated a modest increase compared to the second quartile (Q2). Multivariate analysis confirmed SII as an independent predictor of 28-day mortality (adjusted HR for Q4: 3.04, 95% CI 1.30-7.10, P = 0.005). Subgroup analysis showed the strongest association in patients with congestive heart failure (HR: 1.48, 95% CI 1.26-1.88, P = 0.005).
conclusionsSII exhibits a threshold effect on post-MI mortality, where values exceeding 770 × 10⁹/L independently predict adverse outcomes, suggesting its potential as a prognostic tool for early risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.